Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ · Manufacturing · Pharmaceutical preparations
$2.74−$0.0100 (−0.36%) on the dayAs of the close; data may be delayed.
ZNTL price, last 12 months
Key stats
- Previous close
- $2.75
- Open
- $2.75
- Day range
- $2.65 – $2.77
- 52-week range
- $1.21 – $6.95
- Volume
- 674.1K
- Avg volume (20 days)
- 945.5K
- Market cap
- $255.6M
Performance
1W−11.9%
1M−29.6%
3M−32.2%
6M+2.6%
YTD+103.0%
1Y+80.3%
vs S&P 500, 1Y+63.5 pts
Technicals and fundamentals
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $255.6M